Codice QR

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial

A phase III clinical trial in treatment-naïve patients with chronic hepatitis B (CHB) revealed the safety and considerable therapeutic efficacy of a vaccine containing both hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) at the end of treatment (EOT) and 24 weeks af...

Descrizione completa

Salvato in:
Autori principali: Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Eduardo Penton, Guillen Nieto Gerardo, Yoichi Hiasa
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2021-11-01
Serie:Pathogens
Soggetti:
chronic hepatitis B
therapeutic vaccine
sustained effects
nasal vaccine
NASVAC
HBsAg/HBcAg vaccine
Accesso online:https://www.mdpi.com/2076-0817/10/11/1440
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi